

Jens Kuhle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5728506/publications.pdf>

Version: 2024-02-01

231
papers

15,628
citations

27035

58
h-index

24511

114
g-index

236
all docs

236
docs citations

236
times ranked

11722
citing authors

#	ARTICLE	IF	CITATIONS
1	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	1.4	10
2	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Multiple Sclerosis Journal, 2022, 28, 573-582.	1.4	17
3	Microstructure-Weighted Connectomics in Multiple Sclerosis. Brain Connectivity, 2022, 12, 6-17.	0.8	4
4	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
5	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
6	Serum NFL levels in the first five years predict 10-year thalamic fraction in patients with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110693.	0.5	3
7	Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD). Movement Disorders, 2022, 37, 435-436.	2.2	9
8	Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study. Journal of Neural Transmission, 2022, 129, 295-300.	1.4	10
9	Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome. Brain and Behavior, 2022, 12, e2494.	1.0	3
10	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science, 2022, 375, 296-301.	6.0	892
11	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nature Reviews Neurology, 2022, 18, 158-172.	4.9	205
12	Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210805.	1.5	8
13	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and Neuroinflammation, 2022, 9, .	3.1	32
14	Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia. Annals of Neurology, 2022, 91, 676-681.	2.8	8
15	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology, 2022, 13, 852563.	2.2	18
16	Development of an age-adjusted model for blood neurofilament light chain. Annals of Clinical and Translational Neurology, 2022, 9, 444-453.	1.7	19
17	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	2.2	1
18	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	4.9	210

#	ARTICLE	IF	CITATIONS
19	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. <i>Annals of Neurology</i> , 2022, 91, 814-820.	2.8	7
20	Blood Neurofilament Light in Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	18
21	Diabetes, Glycated Hemoglobin (<scp>HbA1c</scp>), and Neuroaxonal Damage in Parkinson's Disease (<scp>MARK&€PD Study</scp>). <i>Movement Disorders</i> , 2022, 37, 1299-1304.	2.2	22
22	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. <i>Frontiers in Neuroscience</i> , 2022, 16, 819010.	1.4	15
23	Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation. <i>JCI Insight</i> , 2022, 7, .	2.3	5
24	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 682.	4.5	41
25	Increased Neurofilament Light Chain Is Associated with Increased Risk of Long-Term Mortality in Cerebral Small Vessel Disease. <i>Journal of Stroke</i> , 2022, 24, 296-299.	1.4	2
26	A New Advanced <scp>MRI</scp> Biomarker for Remyelinated Lesions in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 92, 486-502.	2.8	28
27	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 972-977.	0.9	7
28	Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
29	Decreased neurofilament light chain levels in estriol&€treated multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1316-1320.	1.7	8
30	Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2081-2089.	1.4	2
31	Lifestyle factors in multiple sclerosis disability progression and silent brain damage: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104016.	0.9	5
32	De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1230-1239.	1.4	20
33	Neurofilament levels are associated with blood&€brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	1.4	55
34	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. <i>Multiple Sclerosis Journal</i> , 2021, 27, 439-448.	1.4	8
35	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 52-60.	1.4	41
36	Comparative analysis of dimethyl fumarate and fingolimod in relapsing&€remitting multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 941-949.	1.8	16

#	ARTICLE	IF	CITATIONS
37	Increasing cancer risk over calendar year in people with multiple sclerosis: a caseâ€“control study. <i>Journal of Neurology</i> , 2021, 268, 817-824.	1.8	6
38	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	3
39	High serum neurofilament associates with diffuse white matter damage in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	25
40	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with highâ€“dose pharmaceuticalâ€“grade biotin (MD1003). <i>Brain and Behavior</i> , 2021, 11, e01998.	1.0	3
41	Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 901-909.	1.7	8
42	Serum neurofilament light chain as outcome marker for intensive care unit patients. <i>Journal of Neurology</i> , 2021, 268, 1323-1329.	1.8	11
43	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 50-55.	1.4	28
44	Quantification of the Neurofilament Light Chain Protein by Single Molecule Array (Simoa) Assay. <i>Neuromethods</i> , 2021, , 223-233.	0.2	0
45	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2021, 89, 610-616.	2.8	68
46	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 388-393.	1.0	8
47	Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. <i>Critical Care</i> , 2021, 25, 32.	2.5	16
48	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. <i>Human Brain Mapping</i> , 2021, 42, 2399-2415.	1.9	10
49	Mass Cytometry of CSF Identifies an MS-Associated B-cell Population. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	19
50	Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2014-2022.	1.4	28
51	Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 582-589.	0.9	15
52	Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. <i>Journal of Neurology</i> , 2021, 268, 2570-2577.	1.8	14
53	Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general populationâ€“an analysis from the MEMO study. <i>BMC Medicine</i> , 2021, 19, 38.	2.3	24
54	Impact of complement activation on clinical outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 944-950.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. <i>Brain</i> , 2021, 144, 1684-1696.	3.7	61
56	GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation. <i>Frontiers in Neuroscience</i> , 2021, 15, 647535.	1.4	4
57	Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3969-3974.	1.8	16
58	Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. <i>Brain Communications</i> , 2021, 3, fcab084.	1.5	14
59	Predictive value of serum neurofilament light chain for persistent cognitive deficits in elderly depressive patients. <i>Journal of Affective Disorders Reports</i> , 2021, 4, 100095.	0.9	1
60	Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. <i>Journal of Psychosomatic Research</i> , 2021, 144, 110402.	1.2	5
61	Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102810.	0.9	21
62	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	3.1	44
63	The cholesterol autoxidation products, 7-ketocholesterol and 7 β -hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102864.	0.9	3
64	Reply to: Neurofilament Light Chain in Patients with COVID-19 and Bacterial Pneumonia. <i>Annals of Neurology</i> , 2021, 90, 175-176.	2.8	0
65	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 477-489.	2.8	16
66	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e543-e553.	1.5	54
67	The Effect of Depression on Health-Related Quality of Life Is Mediated by Fatigue in Persons with Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 751.	1.1	9
68	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 97, e1466-e1474.	1.5	20
69	Increased Serum Neurofilament Light and Thin Ganglion Cell "Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	29
70	Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. <i>Journal of Psychiatric Research</i> , 2021, 140, 141-148.	1.5	36
71	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	2.6	21
72	Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort. <i>European Journal of Neurology</i> , 2021, 28, 4153-4166.	1.7	10

#	ARTICLE	IF	CITATIONS
73	Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD). <i>Parkinsonism and Related Disorders</i> , 2021, 90, 44-48.	1.1	19
74	GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology. <i>NeuroImage: Clinical</i> , 2021, 29, 102522.	1.4	4
75	Fingolimod in children with Rett syndrome: the FINGORETT study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 19.	1.2	12
76	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	38
77	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	1.4	9
78	Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. <i>Brain Communications</i> , 2021, 3, fcab240.	1.5	9
79	Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. <i>Diagnostic and Prognostic Research</i> , 2021, 5, 17.	0.8	4
80	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. <i>BMJ Neurology Open</i> , 2021, 3, e000192.	0.7	1
81	Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands. <i>Frontiers in Immunology</i> , 2021, 12, 811351.	2.2	4
82	The Multiple Sclerosis Data Alliance Catalogue. <i>International Journal of MS Care</i> , 2021, 23, 261-268.	0.4	3
83	Factors influencing serum neurofilament light chain levels in normal aging. <i>Aging</i> , 2021, 13, 25729-25738.	1.4	38
84	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies. <i>Frontiers in Neuroscience</i> , 2021, 15, 791670.	1.4	2
85	Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. <i>Multiple Sclerosis Journal</i> , 2020, 26, 210-219.	1.4	105
86	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 192-202.	1.8	12
87	Serum NfL levels should be used to monitor multiple sclerosis evolution "Yes". <i>Multiple Sclerosis Journal</i> , 2020, 26, 17-19.	1.4	7
88	Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study. <i>Journal of Neurology</i> , 2020, 267, 153-161.	1.8	7
89	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1670-1681.	1.4	61
90	Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 58.	4.5	135

#	ARTICLE	IF	CITATIONS
91	Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1691-1699.	1.4	67
92	Vitamin D ³ supplementation and neurofilament light chain in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 77-80.	1.0	22
93	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 139-143.	1.7	126
94	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 97-102.	1.4	31
95	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 802-811.	1.8	11
96	Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes. <i>Frontiers in Neurology</i> , 2020, 11, 973.	1.1	8
97	Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease. <i>Lancet, The</i> , 2020, 396, 990.	6.3	0
98	Serum neurofilament light chains in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e895.	3.1	1
99	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2020, 19, 988-997.	4.9	64
100	Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis. <i>Journal of Neuroinflammation</i> , 2020, 17, 293.	3.1	22
101	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102534.	0.9	14
102	Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2213-2220.	1.7	27
103	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 675-684.e2.	0.6	8
104	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, 436-444.	1.5	100
105	Gut microbiota-specific IgA ⁺ B cells traffic to the CNS in active multiple sclerosis. <i>Science Immunology</i> , 2020, 5, .	5.6	132
106	Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study. <i>Frontiers in Neurology</i> , 2020, 11, 735.	1.1	9
107	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102389.	0.9	15
108	Lymphocyte recovery after fingolimod discontinuation in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	18

#	ARTICLE	IF	CITATIONS
109	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	27
110	Cross-modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045905.	0.4	0
111	Serum Neurofilament Levels in Children With Febrile Seizures and in Controls. <i>Frontiers in Neuroscience</i> , 2020, 14, 579958.	1.4	24
112	Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102148.	0.9	21
113	Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	6
114	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	43
115	Neurofilaments: neurobiological foundations for biomarker applications. <i>Brain</i> , 2020, 143, 1975-1998.	3.7	167
116	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020, 94, e2457-e2467.	1.5	61
117	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 945-955.	1.7	35
118	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458.	1.1	15
119	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	2.1	31
120	60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. <i>Frontiers in Neurology</i> , 2020, 11, 156.	1.1	10
121	Growth differentiation factor 15 is increased in stable MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	12
122	Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. <i>Journal of Neurology</i> , 2020, 267, 3476-3478.	1.8	83
123	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. <i>EMBO Molecular Medicine</i> , 2020, 12, e11803.	3.3	73
124	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020, 94, e1201-e1212.	1.5	88
125	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. <i>Neurology</i> , 2020, 94, e1950-e1960.	1.5	45
126	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	24

#	ARTICLE	IF	CITATIONS
127	NfL and pNfH are increased in Friedreich's ataxia. <i>Journal of Neurology</i> , 2020, 267, 1420-1430.	1.8	17
128	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. <i>Nature Communications</i> , 2020, 11, 812.	5.8	316
129	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. <i>Brain Communications</i> , 2020, 2, fcaa166.	1.5	24
130	Serum neurofilament light chain and optical coherence tomography measures in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
131	Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease. <i>Journal of Stroke</i> , 2020, 22, 369-376.	1.4	27
132	Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1669-1677.	2.4	27
133	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019, 76, 1359.	4.5	129
134	Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. <i>Epilepsy and Behavior</i> , 2019, 101, 106432.	0.9	15
135	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1757-1770.	1.7	66
136	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?. <i>Journal of Clinical Lipidology</i> , 2019, 13, 654-663.e1.	0.6	17
137	Plasma proteome in multiple sclerosis disease progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1582-1594.	1.7	21
138	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1556-1564.	1.4	32
139	Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. <i>Neurology</i> , 2019, 93, e968-e974.	1.5	29
140	Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort – a prospective cohort study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 403.	0.9	6
141	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. <i>Neurology</i> , 2019, 93, e1299-e1311.	1.5	129
142	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	15.2	610
143	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
144	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1081-1089.	1.7	43

#	ARTICLE	IF	CITATIONS
145	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 187-194.	1.4	59
146	Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. <i>Neurology</i> , 2019, 92, e1007-e1015.	1.5	346
147	ICâ€Pâ€094: CROSSâ€SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P82.	0.4	0
148	Hepatitis E virus infections in patients with MS on oral disease-modifying treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e594.	3.1	7
149	Blood neurofilament light chain at the doorstep of clinical application. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e599.	3.1	24
150	A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 953.	1.1	17
151	O3â€12â€01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P914.	0.4	0
152	PARP-1 deregulation in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989460.	0.5	10
153	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
154	Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 17-25.	0.9	14
155	Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 678-686.	1.4	148
156	A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 241-246.	0.2	23
157	Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. <i>Hypertension</i> , 2018, 71, 1178-1184.	1.3	29
158	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsingâ€remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 777-785.	1.4	46
159	Exploring the effect of vitamin D₃ supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1280-1287.	1.4	32
160	Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2018, 86, 39-50.	3.0	63
161	Neurofilament light chain predicts disease activity in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e422.	3.1	107
162	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 90, e22-e30.	1.5	148

#	ARTICLE	IF	CITATIONS
163	P3â€²51: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1170.	0.4	1
164	Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731881456.	0.5	16
165	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. <i>European Neurology</i> , 2018, 80, 207-214.	0.6	5
166	Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. <i>Frontiers in Neurology</i> , 2018, 9, 984.	1.1	16
167	ICâ€²04â€²02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETAâ€²AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P7.	0.4	0
168	Neurofilament light chain serum levels correlate with 10â€²year <scp>MRI</scp> outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1478-1491.	1.7	115
169	Serum neurofilament light. <i>Neurology</i> , 2018, 91, e1338-e1347.	1.5	137
170	NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. <i>Neurology</i> , 2018, 91, 755-757.	1.5	11
171	The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. <i>BMC Neurology</i> , 2018, 18, 111.	0.8	44
172	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589.	4.9	1,177
173	The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 112-121.	0.9	104
174	Prodromal symptoms of multiple sclerosis in primary care. <i>Annals of Neurology</i> , 2018, 83, 1162-1173.	2.8	98
175	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. <i>Journal of Neurology</i> , 2018, 265, 1618-1624.	1.8	58
176	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 2382-2391.	3.7	345
177	Serum neurofilament light chain is increased in hereditary spastic paraplegias. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 876-882.	1.7	26
178	Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1093-1094.	0.5	48
179	A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. <i>Swiss Medical Weekly</i> , 2018, 148, w14623.	0.8	34
180	Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden. <i>Journal of Stroke</i> , 2018, 20, 228-238.	1.4	82

#	ARTICLE	IF	CITATIONS
181	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. <i>Neurology</i> , 2017, 88, 826-831.	1.5	168
182	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	2.8	768
183	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
184	Reduced Plasma Levels of 25-Hydroxycholesterol and Increased Cerebrospinal Fluid Levels of Bile Acid Precursors in Multiple Sclerosis Patients. <i>Molecular Neurobiology</i> , 2017, 54, 8009-8020.	1.9	50
185	Serum neurofilament light is sensitive to active cerebral small vessel disease. <i>Neurology</i> , 2017, 89, 2108-2114.	1.5	139
186	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1600-1613.	1.4	28
187	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 112-119.	1.1	63
188	Data quality evaluation for observational multiple sclerosis registries. <i>Multiple Sclerosis Journal</i> , 2017, 23, 647-655.	1.4	64
189	Epstein-Barr virus negative MS: a true phenomenon?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017, 4, e318.	3.1	33
190	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV. , 2017, 58, 5985.		4
191	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90
192	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1270-1272.	0.9	65
193	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. <i>Scientific Reports</i> , 2016, 6, 38737.	1.6	81
194	Natalizumab-induced POU2AF1/Spi-B upregulation. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e223.	3.1	27
195	Multiple Sclerosis and Antibodies against KIR4.1. <i>New England Journal of Medicine</i> , 2016, 374, 1496-1498.	13.9	20
196	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1655-1661.	1.4	517
197	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016, 87, 1076-1084.	1.5	85
198	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2016, 79, 152-158.	2.8	188

#	ARTICLE	IF	CITATIONS
199	Comment: "If you can't measure it, you can't improve it" (Lord Kelvin). <i>Neurology</i> , 2016, 87, 1335-1335.	1.5	2
200	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	1.7	207
201	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. <i>Neuron</i> , 2016, 91, 56-66.	3.8	289
202	Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e244.	3.1	129
203	Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1550-1559.	1.4	202
204	Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e215.	3.1	18
205	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. <i>PLoS ONE</i> , 2016, 11, e0152347.	1.1	38
206	CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 748-755.	1.7	118
207	Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cervical Artery Dissection. <i>Cerebrovascular Diseases</i> , 2015, 40, 222-227.	0.8	51
208	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
209	Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy. <i>Acta Neurologica Belgica</i> , 2015, 115, 445-447.	0.5	1
210	Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 565-573.	0.9	91
211	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	3.7	147
212	Neurofilament light chain. <i>Neurology</i> , 2015, 84, 2247-2257.	1.5	412
213	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2015, 84, 1639-1643.	1.5	153
214	Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1202-1207.	0.9	76
215	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 273-279.	0.9	144
216	The Refinement of Genetic Predictors of Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e96578.	1.1	15

#	ARTICLE	IF	CITATIONS
217	MiR-126: a novel route for natalizumab action?. Multiple Sclerosis Journal, 2014, 20, 1363-1370.	1.4	36
218	Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4 ⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Immunology Research, 2014, 2014, 1-11.	0.9	48
219	Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1355-1362.	1.4	32
220	Multiple sclerosis registries in Europe – results of a systematic survey. Multiple Sclerosis Journal, 2014, 20, 1523-1532.	1.4	58
221	A comparative study of CSF neurofilament light and heavy chain protein in MS. Multiple Sclerosis Journal, 2013, 19, 1597-1603.	1.4	122
222	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	1.1	375
223	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases. Expert Opinion on Medical Diagnostics, 2011, 5, 333-346.	1.6	10
224	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. Expert Opinion on Medical Diagnostics, 2011, 5, 393-410.	1.6	5
225	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86
226	A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. Journal of Neuroimmunology, 2010, 220, 114-119.	1.1	80
227	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.1	3
228	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 371-378.	13.9	236
229	Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. Journal of Neurology, 2007, 254, 160-168.	1.8	52
230	A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies. Frontiers in Neurology, 0, 13, .	1.1	6
231	Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain. Frontiers in Neurology, 0, 13, .	1.1	0